LOGIN  |  REGISTER
Amneal Pharmaceuticals

Dynavax Technologies (NASDAQ: DVAX) Stock Quote

Last Trade: US$11.84 -0.17 -1.42
Volume: 1,884,995
5-Day Change: -1.99%
YTD Change: -15.31%
Market Cap: US$1.550B

Latest News From Dynavax Technologies

EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations" page on... Read More
HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected to be $265 - $280 million Cash position increased to $742 million at year end and expect to be cash flow positive for full year 2024 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Feb. 22, 2024... Read More
EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 22, 2024 , at... Read More
Preliminary full year 2023 HEPLISAV-B® vaccine net product revenue of approximately $213 million , a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments, with total U.S. market share increasing to approximately 44% compared to approximately 35% at the end of 2022 Strengthened financial position with cash, cash equivalents and marketable securities at year end increasing to... Read More
EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT . The presentation will be webcast and may be accessed through the "Events & Presentations"... Read More
EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations"... Read More
Generated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million , a 66% year-over-year increase Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million , compared to prior range of $200 - $215 million Cash and investments increased to $720 million at quarter end; expects positive free cash flow for full year Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Nov.... Read More
EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2023 financial results on Thursday, November 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, November 2, 2023 , at 4:30 p.m. ET /... Read More
EMERYVILLE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference on Wednesday, October 25 at 1:00 p.m. ET . The presentation will be webcast and may be accessed through the "Events &... Read More
EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 12:00 p.m. ET . The fireside chat will be webcast and may be... Read More
Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million , a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million , compared to prior range of $165 - $185 million Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. ,... Read More
EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023 , at 4:30 p.m. ET / 1:30... Read More
EMERYVILLE, Calif. , May 30, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6 at 9:20 a.m. CT Goldman Sachs 44 th Annual... Read More
EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15 , at 1:00 p.m. E.T. The presentation will be webcast and may be accessed through the "Events &... Read More
HEPLISAV-B® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% Strengthened balance sheet with cash and investments of $652 million at quarter end and expects positive free cash flow in 2023 Conference call today at 4:30 p.m. ET... Read More
EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 2, 2023 , at 4:30 p.m. ET / 1:30 p.m. PT... Read More
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8 , at 2:10 p.m. E.T. The presentation will be webcast and may... Read More
HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization in... Read More
2022 total revenue of $723 million , up 64% from $439 million in 2021 HEPLISAV-B ® vaccine net product revenue of $126 million , representing 104% growth compared to 2021 CpG 1018 ® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million , representing year-over-year revenue growth of approximately 30-47% Increased strength of financial... Read More
EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 23, 2023 , at... Read More
EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023 , its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol... Read More
China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023,... Read More
Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and investments of approximately $624 million Phase 1 shingles trial results demonstrate favorable tolerability with similar vaccine... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB